Global Drugs of Ursodeoxycholic Acid Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs of Ursodeoxycholic Acid Market Insights, Forecast to 2034
The drug decreases the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients as an alternative to a surgical procedure to remove the gallstones.
Global Drugs of Ursodeoxycholic Acid market is expected to reach to US$ 1842 million in 2024, with a positive growth of %, compared with US$ 1645 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Drugs of Ursodeoxycholic Acid industry is evaluated to reach US$ 3389.8 million in 2029. The CAGR will be 10.7% during 2024 to 2029.
UDCA is a bile acid used in the treatment of various liver disorders, such as primary biliary cholangitis and primary sclerosing cholangitis. The increasing prevalence of these liver diseases, along with growing awareness about their diagnosis and treatment, is driving market growth. Additionally, advancements in drug formulations, such as the development of extended-release and combination therapies, are further contributing to market expansion. The market is highly competitive, with several pharmaceutical companies actively engaged in the production and distribution of UDCA drugs. However, challenges such as high drug costs, side effects, and limited accessibility in certain regions may hinder market growth.
Report Covers
This report presents an overview of global Drugs of Ursodeoxycholic Acid market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Drugs of Ursodeoxycholic Acid market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Segment by Type
Capsule
Tablet
Gallstone
Hepatopathy
Biliary Disease
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Drugs of Ursodeoxycholic Acid plant distribution, commercial date of Drugs of Ursodeoxycholic Acid, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Drugs of Ursodeoxycholic Acid introduction, etc. Drugs of Ursodeoxycholic Acid Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Drugs of Ursodeoxycholic Acid
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Drugs of Ursodeoxycholic Acid market is expected to reach to US$ 1842 million in 2024, with a positive growth of %, compared with US$ 1645 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Drugs of Ursodeoxycholic Acid industry is evaluated to reach US$ 3389.8 million in 2029. The CAGR will be 10.7% during 2024 to 2029.
UDCA is a bile acid used in the treatment of various liver disorders, such as primary biliary cholangitis and primary sclerosing cholangitis. The increasing prevalence of these liver diseases, along with growing awareness about their diagnosis and treatment, is driving market growth. Additionally, advancements in drug formulations, such as the development of extended-release and combination therapies, are further contributing to market expansion. The market is highly competitive, with several pharmaceutical companies actively engaged in the production and distribution of UDCA drugs. However, challenges such as high drug costs, side effects, and limited accessibility in certain regions may hinder market growth.
Report Covers
This report presents an overview of global Drugs of Ursodeoxycholic Acid market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Drugs of Ursodeoxycholic Acid market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Segment by Type
Capsule
Tablet
Segment by Application
Gallstone
Hepatopathy
Biliary Disease
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Drugs of Ursodeoxycholic Acid plant distribution, commercial date of Drugs of Ursodeoxycholic Acid, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Drugs of Ursodeoxycholic Acid introduction, etc. Drugs of Ursodeoxycholic Acid Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Drugs of Ursodeoxycholic Acid
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices